IceCure Medical shares leapt in pre-market trading after the company issued a commercial update showing brisk real-world uptake of its ProSense breast cancer cryoablation system. The stock climbed 80.8% in pre-open trading following an announcement that the U.S. active install base for ProSense has expanded by 70% since the device received FDA marketing authorization in October 2025.
The company said procedures using ProSense are now being performed across a wide network of major U.S. metropolitan markets, reflecting what it described as accelerating adoption across hospitals, interventional radiology centers and ambulatory care facilities. That geographic and provider diversification was highlighted as evidence the FDA clearance is translating into clinical use.
The commercial update follows other encouraging trends for the platform earlier this year. IceCure reported U.S. ProSense sales rose by more than 30% in the first quarter of 2026 compared with the same period in 2025. The company has also benefited from an endorsement reflected in American Society of Breast Surgeons guidelines, a development the company presented alongside its commercial results.
In another corporate action aimed at addressing investor concerns, IceCure completed a 1-for-30 reverse share split in early June 2026. Company filings and the update stated the reverse split was taken to restore compliance with Nasdaq’s minimum bid price requirement - a move the company said removed a key overhang for investors.
Market conditions on the day of the announcement offered little support, with the Nasdaq falling 1.2% and the S&P 500 slipping 0.6% amid what market commentary called a risk-off tone driven by macroeconomic and technology sector pressures. The sharp divergence between IceCure’s pre-market performance and the broader indices underscored how strongly company-specific developments dominated sentiment around the stock.
Taken together, the company’s update and recent operational milestones appear to have triggered a re-assessment of IceCure’s near-term commercial trajectory by the market. The 70% expansion in the U.S. active install base was cited as tangible evidence that FDA clearance is leading to faster-than-expected adoption, and that data point appears to have prompted investors to materially revise their short-term outlook for the company.
Key context from the announcement includes the magnitude of the install base increase, the spread of procedures across major metropolitan markets, quarter-over-quarter sales growth in the U.S., the guideline endorsement and the completion of a reverse share split to meet Nasdaq listing standards. All of these elements were presented as contributors to the heightened market reaction.